- Carragelose revenues show double-digit growth for the fourth year in a row
- New growth opportunities driven by license agreement with Procter & Gamble, US patent for Marinosolv technology and expansion of Solv4U technology partnerships
- Outlook 2023: Moving forward with business development building on strong technology platforms and new clinical data
The full press release is available as download here: